A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years
Recommended Citation
Lourenco AP, Benson KL, Henderson MC, Silver M, Letsios E, Tran Q, Gordon KJ, Borman S, Corn C, Mulpuri R, Smith W, Alpers J, Costantini C, Rohatgi N, Yang R, Haythem A, Biren S, Morris M, Kass F, Reese DE. A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years. Clin Breast Cancer. 2017 Nov;17(7):516-525.e6.
Document Type
Article
Publication Date
11-1-2017
Publication Title
Clinical breast cancer
Abstract
BACKGROUND: Despite significant advances in breast imaging, the ability to detect breast cancer (BC) remains a challenge. To address the unmet needs of the current BC detection paradigm, 2 prospective clinical trials were conducted to develop a blood-based combinatorial proteomic biomarker assay (Videssa Breast) to accurately detect BC and reduce false positives (FPs) from suspicious imaging findings.
PATIENTS AND METHODS: Provista-001 and Provista-002 (cohort one) enrolled Breast Imaging Reporting and Data System 3 or 4 women aged under 50 years. Serum was evaluated for 11 serum protein biomarkers and 33 tumor-associated autoantibodies. Individual biomarker expression, demographics, and clinical characteristics data from Provista-001 were combined to develop a logistic regression model to detect BC. The performance was tested using Provista-002 cohort one (validation set).
RESULTS: The training model had a sensitivity and specificity of 92.3% and 85.3% (BC prevalence, 7.7%), respectively. In the validation set (BC prevalence, 2.9%), the sensitivity and specificity were 66.7% and 81.5%, respectively. The negative predictive value was high in both sets (99.3% and 98.8%, respectively). Videssa Breast performance in the combined training and validation set was 99.1% negative predictive value, 87.5% sensitivity, 83.8% specificity, and 25.2% positive predictive value (BC prevalence, 5.87%). Overall, imaging resulted in 341 participants receiving follow-up procedures to detect 30 cancers (90.6% FP rate). Videssa Breast would have recommended 111 participants for follow-up, a 67% reduction in FPs (P < .00001).
CONCLUSIONS: Videssa Breast can effectively detect BC when used in conjunction with imaging and can substantially reduce unnecessary medical procedures, as well as provide assurance to women that they likely do not have BC.
Medical Subject Headings
Adult; Biomarkers, Tumor; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Female; Follow-Up Studies; Humans; Mammography; Middle Aged; Multimodal Imaging; Prognosis; Prospective Studies; Proteome; Proteomics
PubMed ID
28624156
Volume
17
Issue
7
First Page
516
Last Page
525
